3-D Matrix Past Earnings Performance
Past criteria checks 0/6
3-D Matrix has been growing earnings at an average annual rate of 11.2%, while the Biotechs industry saw earnings growing at 23% annually. Revenues have been growing at an average rate of 42.4% per year.
Key information
11.2%
Earnings growth rate
30.4%
EPS growth rate
Biotechs Industry Growth | 31.9% |
Revenue growth rate | 42.4% |
Return on equity | -173.0% |
Net Margin | -28.4% |
Last Earnings Update | 31 Jan 2024 |
Revenue & Expenses BreakdownBeta
How 3-D Matrix makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Jan 24 | 3,740 | -1,062 | 4,319 | 514 |
31 Oct 23 | 3,166 | -2,204 | 4,175 | 508 |
31 Jul 23 | 2,718 | -1,913 | 4,198 | 449 |
30 Apr 23 | 2,314 | -2,445 | 3,995 | 451 |
31 Jan 23 | 2,064 | -1,906 | 3,714 | 468 |
31 Oct 22 | 1,850 | -1,032 | 3,452 | 543 |
31 Jul 22 | 1,589 | -1,621 | 2,978 | 638 |
30 Apr 22 | 1,506 | -1,894 | 2,713 | 684 |
31 Jan 22 | 1,319 | -2,516 | 2,527 | 756 |
31 Oct 21 | 1,192 | -2,167 | 2,465 | 775 |
31 Jul 21 | 1,155 | -2,401 | 2,312 | 763 |
30 Apr 21 | 1,024 | -2,012 | 2,168 | 785 |
31 Jan 21 | 871 | -2,524 | 1,951 | 755 |
31 Oct 20 | 828 | -2,708 | 1,836 | 770 |
31 Jul 20 | 740 | -2,666 | 1,800 | 827 |
30 Apr 20 | 672 | -3,096 | 1,846 | 801 |
31 Jan 20 | 641 | -2,796 | 1,842 | 806 |
31 Oct 19 | 524 | -2,799 | 1,731 | 780 |
31 Jul 19 | 417 | -2,767 | 1,610 | 771 |
30 Apr 19 | 328 | -2,554 | 1,497 | 786 |
31 Jan 19 | 254 | -2,481 | 1,419 | 748 |
31 Oct 18 | 243 | -2,320 | 1,446 | 712 |
31 Jul 18 | 214 | -2,136 | 1,434 | 645 |
30 Apr 18 | 228 | -1,866 | 1,363 | 562 |
31 Jan 18 | 713 | -1,410 | 1,392 | 552 |
31 Oct 17 | 689 | -1,244 | 1,373 | 512 |
31 Jul 17 | 673 | -1,199 | 1,316 | 463 |
30 Apr 17 | 615 | -1,392 | 1,285 | 469 |
31 Jan 17 | 138 | -1,798 | 1,192 | 481 |
31 Oct 16 | 120 | -2,453 | 1,092 | 534 |
31 Jul 16 | 103 | -2,555 | 1,107 | 615 |
30 Apr 16 | 141 | -2,459 | 1,181 | 661 |
31 Jan 16 | 171 | -2,331 | 1,164 | 697 |
31 Oct 15 | 151 | -1,776 | 1,233 | 736 |
31 Jul 15 | 145 | -1,812 | 1,242 | 841 |
30 Apr 15 | 99 | -1,994 | 1,185 | 816 |
31 Jan 15 | 51 | -2,054 | 1,189 | 773 |
31 Oct 14 | 58 | -1,972 | 1,092 | 737 |
31 Jul 14 | 60 | -1,819 | 1,028 | 593 |
30 Apr 14 | 107 | -1,525 | 953 | 598 |
31 Jan 14 | 88 | -1,339 | 806 | 550 |
31 Oct 13 | 81 | -1,221 | 739 | 495 |
31 Jul 13 | 79 | -1,086 | 653 | 450 |
Quality Earnings: 7777 is currently unprofitable.
Growing Profit Margin: 7777 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 7777 is unprofitable, but has reduced losses over the past 5 years at a rate of 11.2% per year.
Accelerating Growth: Unable to compare 7777's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 7777 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.9%).
Return on Equity
High ROE: 7777 has a negative Return on Equity (-172.96%), as it is currently unprofitable.